AstraZeneca: Carcinoma trials

The registry lists 19 Carcinoma studies with AstraZeneca as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 1 5Phase 2 4Phase 3 10Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingNCT07720284Phase 3
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results posted
• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results posted
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results posted
• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2Results posted
• Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompletedNCT03519971Phase 3Results posted
• Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingNCT03091192Phase 3Results posted
• Phase I, Study in Chinese NSCLC PatientsCompletedNCT02529995Phase 1Results posted
• SELINE: Second-Line Iressa Phase IV Study in NSCLC PatientsCompletedNCT00608868Phase 4Results posted
• The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck CancerCompletedNCT00243347Phase 1Results posted
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06417814Phase 3
• Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerCompletedNCT01352884Phase 1
• A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult PatientsCompletedNCT00613652Phase 1
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3